AJMC August 25, 2024
In this review, authors explain the supply chain issues of getting a life-saving treatment “vein to vein.”
Celltrion’s adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.
Celltrion Adalimumab Partnership With Costco
Celltrion USA has announced that its FDA-approved biosimilar adalimumab-aaty (Yuflyma), a high-concentration, citrate-free alternative to Humira, is now included in the Costco Member Prescription Program.1 This biosimilar is approved for conditions including rheumatoid arthritis, juvenile idiopathic arthritis, and Crohn disease.
Since October 1, 2023, adalimumab-aaty has been available through Costco Specialty Pharmacy for self-funded employer plans. The new announcement means that the biosimilar is now accessible...
Today's Sponsors
Today's Sponsor